In clinical trials, navitoclax has shown promise, particularly in combination therapies. Studies have demonstrated its potential to improve outcomes when combined with other agents like rituximab and ibrutinib in CLL. However, the drug's efficacy is often balanced by its side effect profile, necessitating careful consideration in its clinical use.
